Daiichi Sankyo Company, Limited Withdraws U.S. BLA for I-DXd in ES-SCLC

Daiichi Sankyo voluntarily withdrew the U.S. accelerated approval BLA for ifinatamab deruxtecan in previously treated ES-SCLC after FDA said current data, including from phase 2 IDeate-Lung01, do not support approval. Enrollment continues in the phase 3 IDeate-Lung02 trial.Material DetailsContext b…